Rankings
▼
Calendar
TELO Q2 2022 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
Q2 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$70,064
Net Income
-$70,064
EPS (Diluted)
$-0.00
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
$0
Free Cash Flow
$0
Stock-Based Comp.
$0
← FY 2022
All Quarters
Q3 2022 →
